Buy cannabis-play GW Pharmaceuticals, Goldman says

A cannibanoid medecine manufactured by GW Pharmaceuticals.
BSIP | UIG | Getty Images

Investors should buy shares of GW Pharmaceuticals on its promising cannabis-based drug pipeline, according to Goldman Sachs, which started coverage of the company with a buy rating.

"We initiate coverage on GWPH, a pre-commercial-stage biopharmaceutical company focused on cannabis-based therapies in central nervous system (CNS) disorders," Goldman's Salveen Richter wrote in a note to clients Friday. "GWPH [is] set to fly high. ... A barrage of pipeline catalysts should drive shares higher in 4Q16."

Richter's picks have a 31.5 percent one-year average return with a 70 percent success rate, according to analyst ranking service TipRanks, placing him in the top 2 percent of all Wall Street analysts covering any industry.

More In Pro News and Analysis

CNBC ProWhen the bond market flashes a recession warning, these are the stocks to consider, Trivariate says
CNBC ProDeere, Matterport and more: CNBC's 'Halftime Report' traders answer your stock questions
CNBC ProThis growth fund is among the best this year with a 13% return. Here’s what it’s buying now